On April 25, Pfizer announced that its oral targeted drug Inlyta (generic name: axitinib tablets) was approved by the National Medical Products Administration (NMPA) on April 22, 2025, combined with toripalimab for the first-line treatment of patients with intermediate- and high-risk unresectable or metastatic renal cell carcinoma (RCC). According to it, this is also the first and only first-line target-immune combination therapy approved in the field of renal cancer treatment in China.